Category: HeartWare International Inc.
Shares of HeartWare International gain after the medical device company reports positive results for a post-approval study of its HVAD implantable heart pump.
HeartWare International (NSDQ:HTWR) shares are up today on the medical device company's 1st release of data since its HVAD implantable heart pump went on the U.S. market.
Hedge fund giant BlackRock boosted its stake in a number of medical device companies last year, but cut its holdings in others, regulatory filings show.
Wright Medical Group Inc.
, Align Technology Inc.
, ArthroCare Corp.
, AtriCure Inc.
, Biolase Technology Inc.
, BlackRock Inc.
, Cutera Inc.
, Cynosure Inc.
, Dentsply International Inc.
, HeartWare International Inc.
, ICU Medical Inc.
, Medical Action Industries Inc.
, Merit Medical Systems Inc.
, NxStage Medical Inc.
, Thoratec Corp.
HeartWare shares come under pressure after the medical device company reports higher-than-expected losses for the 4th quarter and 2013.
Investors punished HeartWare International (NSDQ:HTWR) today for missing expectations with its 4th-quarter and full-year results, paring some 3% from HTWR shares.
HeartWare International's 4th-quarter preliminary sales numbers miss the mark on Wall Street, prompting investors to send its share price down.
HeartWare International (NSDQ:HTWR) said it expects to report 4th-quarter revenues of roughly $53 million, missing the consensus view on Wall Street of $58 million and sending its share price down sharply in pre-market trading.
HeartWare CEO Doug Godshall tells MassDevice.com about the 6-year journey to the $350 million acquisition of heart pump maker CircuLite.
HeartWare International acquires CircuLite in a cash-and-stock deal that could eventually be worth up to $350 million.
Shares of Thoratec Corp. slide after the New England Journal of Medicine publishes results showing a sharp increase in rates of blood clots in patients implanted with the medical device company's HeartMate II left ventricular assist device.
Thoratec (NSDQ:THOR) shares are under pressure after a New England Journal of Medicine study showing a sharp increase in the rate of thrombosis, or blood clots, in patients implanted with its HeartMate II left ventricular assist device.